Vertex Reported Positive Phase 2b Trial Results
The company announced promising data for its kidney disease drug candidate, inaxaplin, in a phase 2b study.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Should the government prioritize accelerated approval for new drugs targeting rare, underlying genetic diseases?
Vertex Pharmaceuticals reported positive phase 2b trial results for its once-daily oral drug, inaxaplin, which showed significant reductions in protein levels for patients with kidney disease. The study evaluated the drug as an add-on therapy to standard care for those living with APOL1-mediated kidney disease.
Why it matters
These results provide a potential path toward new treatment options for APOL1-mediated kidney disease, which affects approximately 150,000 individuals across the United States and Europe. Positive findings in upcoming trials could lead to accelerated regulatory approval for the drug in the U.S. market.
The study utilized a 45 mg once-daily oral dose of inaxaplin, with no reported serious adverse events. Efficacy was measured by a change in urine albumin to creatinine ratio at Week 13 compared to baseline.
The players
Vertex Pharmaceuticals
This Boston-based biotechnology company is a leader in developing innovative medicines for serious diseases.
The details
The AMPLIFIED study enrolled 41 participants to assess the efficacy of inaxaplin when added to an optimized standard of care regimen. While headache was noted in over 5% of subjects, the trial reported no serious drug-related adverse events during the observation period.
Timeline
Week 13: Efficacy endpoints were measured for the AMPLIFIED study.
Early 2027: Expected timeline for interim analysis results from the AMPLITUDE trial.
The Big Picture
This development represents a significant step forward in the broader medical effort to address genetically driven kidney disorders. These findings validate the therapeutic approach used in the AMPLITUDE clinical trial and mark a major progression in the company's renal pipeline.
Patients with APOL1-mediated kidney disease may see a new, once-daily oral treatment option if clinical milestones continue to be met. The trial's success suggests a move toward more convenient, non-invasive therapeutic management compared to current standards of care.
The takeaway
These findings represent a critical advancement in targeting the root cause of APOL1-mediated kidney disease. Patients and healthcare providers should monitor upcoming trial updates for potential changes in the standard of care.
What happens next
Vertex expects to release interim analysis results for the ongoing phase 2/3 AMPLITUDE clinical trial in early 2027, which could support a request for accelerated approval from regulators.
Further reading
For more information on the latest industry developments, see the Biotech section.
Live Poll
Should the government prioritize accelerated approval for new drugs targeting rare, underlying genetic diseases?
